News

SRX Global (AMEX:SRXH) disclosed an investment in Vistagen Therapeutics (NASDAQ:VTGN) and said it intends to engage with the company’s leadership and board on potential shareholder value initiatives. Key Investor TakeawaysSRX Global (AMEX:SRXH) acquired a stake in Vistagen Therapeutics (NASDAQ:VTGN).

Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) share price after Monday's sharp fall, while Deutsche Bank sees clear parallels with the drugmaker's Alexion acquisition five years ago. The two notes are the second-day response to a...

Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert, and only one of them is a clean fit.

Ex-Uber founder and CEO Travis Kalanick is back in the ride-hail business — but this time in the skies.

Ex-Uber founder and CEO Travis Kalanick is back in the ride-hail business — but this time in the skies.

IREN now controls more of the stack between its data centers and customer workloads, extending its AI cloud platform into orchestration and enterprise support.

AstraZeneca (LSE:AZN) is reported to be in advanced merger talks with Bristol Myers Squibb. The potential deal could create a combined pharmaceutical company valued at about US$400b. The transaction, if completed, would rank among the largest in the sector and could significantly affect competitive positions in oncology. Regulators are expected to review any agreement closely due to overlapping product portfolios. AstraZeneca is a global pharmaceutical company with a significant focus on...

The pharma giant now expects adjusted earnings of $2.66 to $2.76 per share, down from a prior range of $5.04 to $5.16

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.

Merck slashed its profit outlook for the year due to charges tied to its acquisition of cancer biotech company Terns Pharmaceuticals.

Chinese robot maker Unitree Technology is expected to be valued ‌at more than 50 billion yuan ($7.4 billion) after its planned ‌Shanghai IPO, according to a report by Citic Securities, which is sponsoring the initial ​public offering. Citic Securities expected the Hangzhou-based company to be worth 50.6 billion to 55.9 billion yuan six to 12 months after listing later this month. The valuation report, distributed to investors and seen by ‌Reuters, is largely seen ⁠as guidance ahead of Wednesday's IPO price enquiry.

SpaceX (NASDAQ:SPCX) is due to publish its quarterly results after the close of trading on Tuesday, marking the company’s first earnings report since its highly anticipated stock market debut. The release is expected to provide investors with a clearer picture of whether the company’s financial performance supports the ambitious growth expectations that accompanied its listing, particularly as it continues to invest heavily in artificial intelligence and space technologies.

Robinhood (NASDAQ:HOOD) is seeking to raise up to $200 million through the U. S.

The transaction was first announced in March, when Mastercard signed an agreement to acquire BVNK for up to $1.8bn.

Big drug companies have been buying scrappy biotechs to expand their pipelines, but the potential megamerger between AstraZeneca and Bristol Myers Squibb could flip that script.

Electrical connector manufacturer Amphenol (NYSE:APH) announced better-than-expected revenue in Q2 CY2026, with sales up 55% year on year to $8.76 billion. On top of that, next quarter’s revenue guidance ($9.35 billion at the midpoint) was surprisingly good and 7.1% above what analysts were expecting. Its non-GAAP profit of $1.35 per share was 13.2% above analysts’ consensus estimates.

Elon Musk’s net worth continued to plunge this week as shares of his two flagship companies, Tesla and SpaceX, retreated amid swirling merger speculation, with traders also positioning ahead of SpaceX’s upcoming earnings report. Elon Musk Net Worth is Down...

Mastercard finally closed its acquisition of London-based stablecoin infrastructure provider BVNK on August 3, 2026. If you have ever wondered what happens when the plumbing of global finance decides to move inside the house, this is your answer. It is not just another corporate press release about a strategic partnership; it is the moment the […]

Another SMR stock is expected to make its public debut.

Investors questioned whether combining AstraZeneca with Bristol Myers would strengthen growth enough to justify the financial and regulatory risks.

The Ark Invest founder is betting big on SpaceX.

Suze Orman walked through a real SpaceX IPO trade that turned $10,000 into roughly $5,600 in seven weeks, and her lesson has nothing to do with rockets or Elon Musk.

The Bithumb crypto exchange is preparing for a 2028 initial public offering (IPO) after reorganizing its business and setting out a two-year program to strengthen accounting, compliance and risk controls. South Korea’s largest cryptocurrency exchange said it expects to complete internal-control ...

Apple's Latest Acquisition Signals a Bigger Push Into AI and Advanced Chips

The UK drugmaker is reportedly talking to Bristol Myers Squibb about a nearly $400 billion tie-up, but investors are struggling to diagnose the logic.

The fund holds 80 private companies and focuses on Y Combinator startups, with shares expected to list on the NYSE on August 13

Rocket Lab is rapidly transforming from a launch company into a diversified space business, positioning it for profits and strong free cash flow as early as next year.

CXMT closed its first day of trading at 49 yuan on July 27, 466% above its 8.66-yuan offer price. The Chinese DRAM maker raised about $8.6 billion in Asia’s largest IPO this year, ending the session valued at roughly $488 billion. With only 6.73% freely tradable, the small float could magnify price swings. The listing […]

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.